Proteolytic degradation products of fibrinogen, produced as a result of excessive fibrinolysis, have been demonstrated in the blood of cirrhotic patients. 7,8 Such degradation products, when formed in ...

Approximately 40% of adolescent women experience heavy menstrual bleeding (HMB), and 10–62% of them have an underlying bleeding disorder (BD). Diagnosing a BD remains challenging because of ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

Prasugrel provided a more rapid reduction in platelet aggregation than clopidogrel in patients with stable coronary artery disease on dual antiplatelet therapy and an impaired renal function, ...

Patients on prasugrel therapy have greater platelet inhibition than those taking maintenance doses of clopidogrel and thus require a longer time to return to baseline reactivity after stopping the ...

pills According to the investigators, nearly 25% of patients with CKD have MDD, and both conditions are independent risk factors for cardiovascular events. Treatment of major depressive disorder (MDD) ...

Please provide your email address to receive an email when new articles are posted on . Published data did not support the theory that rebounding blood platelets account for clusters of thrombotic ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

The global Platelet Aggregation Devices Market is valued at USD 590.65 Million in 2024 and is projected to reach a value of USD 1086 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 5.75% ...

DUBLIN--(BUSINESS WIRE)--The "Global Platelet Aggregation Devices Market - Segmented by Product (Systems, Reagents, Consumables and Accessories), Application, End User and Geography - Growth, Trends ...